1380227-39-3

Basic information

• Product Name: 4-(4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide
• Synonyms: 4-(4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide
• CAS NO: 1380227-39-3
• Molecular Weight: 452.494
• Mol File: 1380227-39-3.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide(1380227-39-3)
• EPA Substance Registry System: 4-(4-(2-morpholino-4-oxo-1,4-dihydroquinolin-8-yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide(1380227-39-3)

Safety Data

• Hazardous Substances Data: 1380227-39-3(Hazardous Substances Data)

Upstream product

• 1380228-29-4 5-((2-iodophenylamino)(morpholino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1380228-27-2 5-((2-iodophenylamino)(methylthio)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 615-43-0 2-iodophenylamine 
• 1380228-35-2 8-ethynyl-2-morpholinoquinolin-4(1H)-one 
• 36326-86-0 4-azidobenzenesulfonamide 
• 1380228-33-0 2-morpholino-8-((trimethylsilyl)ethynyl)quinolin-4(1H)-one 
• 1380228-31-8 8-iodo-2-morpholinoquinolin-4(1H)-one 

Relevant articles and documents

Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs

Activation of the phosphoinositide 3-kinase (PI3K) pathway is a key signaling event in cancer, inflammation, and other proliferative diseases. PI3K inhibitors are already approved for some specific clinical indications, but their systemic on-target toxicity limits their larger use. In particular, whereas toxicity is tolerable in acute treatment of life-threatening diseases, this is less acceptable in chronic conditions. In the past, the strategy to overcome this drawback was to block selected isoforms mainly expressed in leukocytes, but redundancy within the PI3K family members challenges the effectiveness of this approach. On the other hand, decreasing exposure to selected target cells represents a so-far unexplored alternative to circumvent systemic toxicity. In this manuscript, we describe the generation of a library of triazolylquinolones and the development of the first prodrug pan-PI3K inhibitor.

QUINOLIN-4 (1H) -ONE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES

Compounds of Formula (I): able to inhibit kinase activity, in particular Phosphatidylinositol 3-Kinases activity. The disclosure also relates to the use of compounds of Formula (I) for treatment of pathological conditions associated to alterations in Phos

QUINOLIN-4 (1H) -ONE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES

Compounds of Formula (I): able to inhibit kinase activity, in particular Phosphatidylinositol 3-Kinases activity. The disclosure also relates to the use of compounds of Formula (I) for treatment of pathological conditions associated to alterations in Phos